CBD and breastfeeding: what studies say in 2026

CBD and breastfeeding are a combination that medical professionals currently advise against. In the absence of clinical studies establishing its safety in infants, the safest course of action remains to avoid all CBD consumption while breastfeeding, or to discuss it immediately with a healthcare professional if you have already used CBD.

If you have recently consumed CBD, here are the first steps to take:

Contact your doctor, midwife, or lactation consultant to assess the situation with you.
Note precisely the form of the product (oil, flower, resin), the estimated dose and the time of intake.
Monitor your baby in the following hours: unusual drowsiness, difficulty breastfeeding, changes in muscle tone.

This caution is based on a simple principle: in the absence of reassuring data, the risk must be ruled out by default, and the final decision is always made in consultation with a healthcare professional, never alone in front of a forum or a product leaflet.

Key points

CBD passes into breast milk and no clinical studies to date guarantee its safety for breastfed infants.

Point	Details
Cautionary verdict	Avoiding CBD while breastfeeding remains the safest recommendation in the absence of reassuring clinical data.
Passage confirmed in milk	CBD has been detected in breast milk after consumption, according to published pharmacological data.
Risk of contamination	Commercial products may contain THC or other undeclared substances, a risk documented by the ANSM.
Drug interactions	CBD inhibits liver enzymes and may alter the effect of anticoagulants, antiepileptics, and immunosuppressants.
Research in progress	The French clinical trial NCT06589258 is currently measuring the passage of CBD into milk and its impact on the child.

This article provides general information and is not a substitute for professional medical advice. Consult a qualified healthcare professional about your specific situation before taking any action based on this content.

CBD and breastfeeding: essential facts to know
What is CBD and how does it differ from THC?
What do we know about the passage of CBD into breast milk?
Known and unknown risks in exposed infants
Drug interactions of CBD and effects on the mother
What do the authorities and lactation organizations say?
Practical advice if you are breastfeeding and have consumed CBD
Can the ongoing research change the situation?
A word from the author
Sources

CBD and breastfeeding: essential facts to know

Cannabidiol crosses the breast milk barrier after consumption, a finding confirmed by several recent pharmacological studies; the question is therefore not whether it passes, but in what quantity and with what consequences for the infant. No clinical study has yet established a safe exposure threshold for breastfed infants.

Some useful points to consider before going any further:

CBD has been detected in breast milk after consumption, according to published pharmacological data.
The use of cannabis and CBD is increasing among young adults, a phenomenon documented by recent reviews on lactation.
Products sold as CBD may contain traces of THC or other substances, a problem regularly reported by the ANSM.

The key point to remember: neither CBD nor THC currently has sufficient clinical data to guarantee safe exposure in breastfed infants.

What is CBD and how does it differ from THC?

CBD (cannabidiol) and THC (tetrahydrocannabinol) are two molecules extracted from hemp or cannabis, but they do not act on the body in the same way. THC is psychoactive and responsible for the "high"; CBD, on the other hand, does not have this euphoric effect, which partly explains its image as a "mild" and "natural" product. However, this reputation says nothing about its safety during breastfeeding.

The two molecules share a characteristic that worries researchers: their high lipophilicity, meaning their affinity for fats. Since breast milk is rich in lipids, cannabinoids tend to concentrate and be stored there for a long time, with a long half-life that prolongs the infant's exposure well after the last maternal intake.

Three key points to keep in mind:

CBD is not euphoric, but it remains an active molecule on the central nervous system.
Its lipophilicity promotes its passage and accumulation in breast milk.
Commercial products vary enormously in purity: an article details the essential differences between hemp, cannabis, CBD and THC to better understand this variability.

A consumer who thinks they are buying a "pure CBD" product may therefore unknowingly expose their child to THC or undeclared synthetic cannabinoids.

What do we know about the passage of CBD into breast milk?

Scientific data confirms that CBD passes into breast milk, but it remains too limited to establish reliable dosage guidelines or withdrawal periods. Researchers have pharmacokinetic models built from small samples, but no large-scale clinical trials.

A review mentions a pharmacokinetic model built on data from 181 mothers, a study that outlined the general transfer of cannabinoids into breast milk but did not establish a safety standard applicable to all situations, as Information Pour l'Allaitement. Reference chapters in the NCBI Bookshelf also detail the mechanisms of cannabinoid transfer to breast milk, confirming that the molecule gradually accumulates there with repeated intake.

Faced with this lack of robust data, France has launched a concrete response:

A clinical trial designated CBD-ALLT (ID NCT06589258) is currently measuring, by tandem mass spectrometry, the actual passage of CBD into the blood and breast milk, as well as its biological impact on the breastfed infant.

This essay represents the first French attempt to objectify, with precise analytical tools, what international literature has only been estimating for several years.

The methodological limitations of the available studies remain significant:

Samples of participants are often small, rarely representative of the diversity of maternal profiles.
Many studies confuse exposure during pregnancy with exposure during breastfeeding, two very different biological windows.
No studies have yet followed children exposed over the long term to assess possible consequences on their development.

Reference point: to date, no published data allows us to establish a reliable waiting period between taking CBD and resuming breastfeeding without risk.

Known and unknown risks in exposed infants

Published clinical cases report acute effects in infants exposed to cannabis through breast milk: excessive drowsiness, breastfeeding difficulties, and, more rarely, apnea or seizures reported in cases of significant exposure. These cases remain few in number, but they are sufficient to justify genuine vigilance rather than trivializing the drug.

In animal studies, recent results are more worrying to researchers than isolated clinical cases in humans:

Studies conducted on mice and monkeys show alterations in brain development after exposure to CBD, according to a 2024 government report.
ANSES has proposed classifying CBD as presumed toxic to human reproduction, a classification based in particular on these animal data.
Some analyses suggest a possible risk for breastfed babies, although this risk has not been quantified in humans.

The evidence available today is sufficient to warrant caution, but it is not sufficient to accurately describe the nature or extent of the actual risk to an infant exposed to low doses on an occasional basis.

It is precisely this gray area, between warning sign and scientific certainty, that complicates counseling for breastfeeding mothers. The effects of chronic low-dose exposure, those of a single dose, and the long-term consequences on neurological development remain three questions without definitive answers to date.

Drug interactions of CBD and effects on the mother

CBD is not inert for the maternal body: it inhibits certain liver enzymes of the cytochrome P450 system, the same enzymes that metabolize many common medications. This inhibition can alter the blood concentration of other treatments, either increasing or decreasing it.

Several classes of drugs are involved in this mechanism, as documented in a pharmacological analysis published on PMC :

Anticoagulants, with a risk of overdose and bleeding.
Anti-epileptic drugs, whose effectiveness may be disrupted.
Immunosuppressants are particularly sensitive to variations in plasma concentration.

An undetected interaction can therefore affect the mother's health long before posing a direct problem for the child, which justifies a systematic review of ongoing treatments.

Pro tip: If you are taking any chronic medication, talk to your pharmacist before considering CBD in any form. A simple interaction check can prevent many unnecessary complications.

What do the authorities and lactation organizations say?

No major health agency or lactation organization recommends the use of CBD during breastfeeding, due to a lack of sufficient data.

The synthesis of these positions identifies three common themes:

Avoid consuming CBD (and cannabis in general) for the entire duration of breastfeeding.
Prioritize a shared decision between the mother and her healthcare professional rather than a blunt and anxiety-inducing prohibition.
To recognize that no waiting period has been scientifically validated for resuming breastfeeding after occasional consumption.

French-language reference guides on lactation, such as those published by La Leche League France, apply the precautionary principle to psychoactive substances during breastfeeding and systematically encourage dialogue with a professional rather than the abrupt and guilt-inducing cessation of breastfeeding.

The WHO pre-evaluation report on cannabidiol also points to a glaring lack of data in the perinatal period, calling for further research before any definitive recommendation on an international scale.

Practical advice if you are breastfeeding and have consumed CBD

A single exposure does not justify panic or abruptly stopping breastfeeding without medical advice. Here are the steps to follow, step by step.

Observe your baby in the 24 hours following administration: appetite, tone, sleep, responsiveness.
Note the exact product consumed (brand, form, dosage indicated) and the time of intake; this information will help any professional consulted.
Contact your doctor, midwife or a poison control center if you have any doubt about the dose or composition of the product.
Discuss with an IBCLC-certified lactation consultant the options best suited to your specific situation.

Certain signs in infants should raise immediate concern:

Unusual drowsiness or sudden difficulty breastfeeding.
Irregular breathing or pauses in breathing.
Any abnormal movement suggestive of a seizure.

If you notice any of these signs, contact a pediatric emergency service immediately.

To manage postpartum anxiety, pain or insomnia without resorting to CBD, several validated alternatives exist: psychological support, certain analgesics compatible with breastfeeding prescribed by a doctor, cognitive-behavioral therapy for anxiety, or even supervised relaxation techniques.

Pro tip: Keep a written record of any CBD products you may have used before discovering your pregnancy or while breastfeeding. This information, even if added later, remains valuable to your doctor.

Can the ongoing research change the situation?

The CBD-ALLT clinical trial (NCT06589258) conducted in France is the first study specifically designed to measure, using rigorous analytical methods, the actual transfer of CBD into breast milk and its biological impact on the breastfed infant. This approach changes the nature of the debate: instead of relying on extrapolations from animal studies, it will produce directly usable human data.

Reports published between 2024 and 2025 by the French authorities simultaneously fuel the prevailing caution:

Animal studies relayed by Drogues.gouv.fr document neurodevelopmental alterations that need monitoring.
The Anses classification proposal strengthens the regulatory framework surrounding the product.

The results of the CBD-ALLT trial will probably not change the recommendation of caution in the short term, but they will finally allow us to quantify a risk that is currently only suspected.

For mothers as well as clinicians, waiting remains the best reasonable option: this data will arrive with its own methodological limitations, but it will constitute the first solid, breastfeeding-specific basis on which to base future recommendations.

At Thefrenchhempempire, this requirement for traceability and independent laboratory analysis already guides the selection of all products offered, a principle that takes on its full meaning when faced with a subject as sensitive as breastfeeding.

A gloved hand holds a bottle of hemp oil in a laboratory.

A word from the author

I understand the temptation to seek quick relief from postpartum exhaustion. But caution here isn't a moralizing stance; it's an honest response to a lack of data. Until science provides a definitive answer, the best decision remains one made with a healthcare professional, not alone, relying solely on a product label.